Benzinga | May 24, 2021 10:36AM EDT

Synlogic Sunday Afternoon Highlighted Presentation Of Data On Novel Approach For Treatment Of Inflammatory Bowel Disease At Digestive Week

Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an investigational program to develop Synthetic Biotic(tm) medicines for the treatment of inflammatory bowel disease (IBD) during Digestive Disease Week (DDW), being held virtually May 21-23, 2021.

The presentation, "A Novel IL-22-Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease," was delivered by Mylene Perreault, Synlogic's Senior Director and Head of Biology. The presentation recording will be available throughout the duration of the conference.

Learn more about Synlogic's programs and development pipeline by visiting https://www.synlogictx.com/.